These findings show improved outcomes in early stage nodal T-cell lymphomas compared to historical data for allcomers. In addition, favorable outcomes in stage I disease treated with chemoradiation support such strategy as an excellent treatment option in this setting.
Current evidence suggests a possible oncogenic interaction between hereditary susceptibility and chronic implant-associated inflammation. Clinicians must maintain vigilance for BIA-ALCL even in prophylactic settings, as early diagnosis and complete surgical excision remain key to favorable outcomes.
This case illustrates the compounding diagnostic pitfalls of oral IMT: dual-site involvement, two failed biopsies, ALK negativity in an elderly patient, and focal cytokeratin positivity risking misclassification as spindle cell carcinoma. Awareness of IMT histologic subtypes, meticulous tissue sampling, and systematic immunohistochemical profiling are essential to avoid misdiagnosis and unnecessary aggressive oncologic treatment.
TP53-D is common in systemic ALK-negative ALCL and is associated with leukemic disease and p53 overexpression. TP53-D did not directly affect survival, but it negated the favorable impact of low IPI and DUSP22-R on PFS, suggesting its potential value as an adverse prognostic marker.
The patient responded favorably to electron beam radiotherapy. This case underscores the importance of early biopsy in atypical or treatment-refractory ulcers and highlights the diagnostic relevance of recognizing rare variants such as the angiocentric subtype.
One patient was known to decease despite chemotherapy. In conclusion, oral manifestations of ALCL are very rare and more commonly represent a disseminated disease.
Given the nonspecific clinical and radiological findings, anaplastic large cell lymphoma should be considered in the differential diagnosis of breast masses, particularly those associated with cystic changes or chronic inflammatory processes. Definitive diagnosis requires thorough histopathological and immunophenotypic evaluation.
Our CT-based deep learning radiomics model holds promise for non-invasive detection of ALK rearrangements in lung adenocarcinoma, yet remains investigational and necessitates prospective multicenter validation before clinical implementation.